P-032 - POPULATION PHARMACOKINETICS OF ZIMBERELIMAB (AB122) AND DOSE JUSTIFICATION BY MODEL INFORMED DRUG DEVELOPMENT (MIDD) APPROACH.

X. Yu¹, A. Chaturvedula², L. Jin², H. Wu¹, P. Foster², D. Colburn², R. Criste¹, B. Agoram²; ¹Amador Bioscience, Pleasanton, CA, USA, ²Arcus Biosciences, Hayward, CA, USA.

Presenting Author(s)

Xiaoying Yu, MS

Associate Scientist
Amador Biosciences
Pleasanton, California, United States